外科領域の感染症に対するCefbuperazoneの有効性に関する検討

甲斐 秀信; 杉町 圭蔵; 玉田 隆一郎; 竹中 賢治; 犬塚 貞光; 夏田 康則; 田口 純一; 小林 迪夫; 金子 隆; 御手洗 義信; 垣迫 健二; 辻 秀男; 安部 良二; 和田 哲哉; 古澤 元之助; 友田 博次; 朔 元則; 古山 正人; 原口 幸昭; 桑野 博行; 藤 也寸志; 嶺 博之; 池田 俊彦; 隈 博政; 坂門 一英; 中山 真一; 大脇 義人; 皆川 清三; 立石 春雄; 森山 正明; 森 彬; 坂田 久信; 岡 直剛; 野田 尚一; 古賀 俊六

doi:10.11553/antibiotics1968b.41.322

CLINICAL STUDIES ON EFFECT OF CEFBUPERAZONE ON SURGICAL INFECTIONS

HIDENOBU KAI, KEIZO SUGIMACHI, RYUICHIRO TAMADA, KENJI TAKENAKA, SADAMITSU INUZUKA, YASUNORI NATSUDA, JUNICHI TAGUCHI, MICHIO KOBAYASHI, TAKASHI KANEKO, YOSHINOBU MITARAI, KENJI KAKISAKO, HIDEO TSUJI, RYOJI ABE, TETSUYA WADA, MOTONOSUKE FURUSAWA, HIROTSUGU TOMODA, MOTONORI SAKU, MASATO FURUYAMA, YUKIAKI HARAGUCHI, HIROYUKI KUWANO, YASUSHI TOH, HIROYUKI MINE, TOSHIHIKO IKEDA, HIROMASA KUMA, KAZUHIDE SAKATO, SHINNCHI NAKAYAMA, YOSHITO OOWAKI, SEIZO MINAGAWA, HARUO TATEISHI, MASAAKI MORIYAMA, AKIRA MORI, HISANOBU SAKATA, NAOKATA OKA, SHOOCHI NODA, SHUNROKU KOGA

Author information

HIDENOBU KAI
The Second Department of Surgery, Faculty of Medicine, Kyushu University
KEIZO SUGIMACHI
The Second Department of Surgery, Faculty of Medicine, Kyushu University
RYUICHIRO TAMADA
The Second Department of Surgery, Faculty of Medicine, Kyushu University
KENJI TAKENAKA
The Second Department of Surgery, Faculty of Medicine, Kyushu University
SADAMITSU INUZUKA
The Second Department of Surgery, Faculty of Medicine, Fukuoka University
YASUNORI NATSUDA
The Second Department of Surgery, Faculty of Medicine, Fukuoka University
JUNICHI TAGUCHI
The Second Department of Surgery, Faculty of Medicine, Fukuoka University
MICHIO KOBAYASHI
The First Department of Surgery, Medical College of Oita
TAKASHI KANEKO
The First Department of Surgery, Medical College of Oita
YOSHINOBU MITARAI
The First Department of Surgery, Medical College of Oita
KENJI KAKISAKO
The First Department of Surgery, Medical College of Oita
HIDEO TSUJI
Department of Surgery, Medical Institute of Bioregulation, Kyushu University
RYOJI ABE
Department of Surgery, Medical Institute of Bioregulation, Kyushu University
TETSUYA WADA
Department of Surgery, Medical Institute of Bioregulation, Kyushu University
MOTONOSUKE FURUSAWA
Department of Gastroenterological Surgery, National Kyushu Cancer Center
HIROTSUGU TOMODA
Department of Gastroenterological Surgery, National Kyushu Cancer Center
MOTONORI SAKU
Department of Surgery, National Fukuoka Central Hospital
MASATO FURUYAMA
Department of Surgery, National Fukuoka Central Hospital
YUKIAKI HARAGUCHI
Department of Surgery, Sawara Hospital
HIROYUKI KUWANO
Department of Surgery, Sawara Hospital
YASUSHI TOH
Department of Surgery, Sawara Hospital
HIROYUKI MINE
Department of Surgery, Sawara Hospital
TOSHIHIKO IKEDA
Department of Surgery, Fukuoka Municipal Daiichi Hospital
HIROMASA KUMA
Department of Surgery, Fukuoka Municipal Daiichi Hospital
KAZUHIDE SAKATO
Department of Surgery, National Fukuoka Higashi Hospital
SHINNCHI NAKAYAMA
Department of Surgery, National Fukuoka Higashi Hospital
YOSHITO OOWAKI
Department of Surgery, Iizuka Hospital
SEIZO MINAGAWA
Department of Surgery, Iizuka Hospital
HARUO TATEISHI
Department of Surgery, Iizuka Hospital
MASAAKI MORIYAMA
Department of Surgery, Saiseikai Yahata Hospital
AKIRA MORI
Department of Surgery, Nippon Steel Yahata Hospital
HISANOBU SAKATA
Department of Surgery, Nippon Steel Yahata Hospital
NAOKATA OKA
Department of Surgery, Saga Prefectural Hospital,“Kouseikan”
SHOOCHI NODA
Department of Surgery, National Beppu Hospital
SHUNROKU KOGA
Department of Surgery, National Beppu Hospital

JOURNAL FREE ACCESS

1988 Volume 41 Issue 3 Pages 322-330

DOI https://doi.org/10.11553/antibiotics1968b.41.322

Details

Abstract

We conducted clinical studies on the efficacy and safety of cefbuperazone (CBPZ) on surgical infections with the following results.
1) In evaluable 32 patients, CBPZ was evaluated to be clinically effective in 23 (71.9%) and the efficacy rate was better in those who were administered 4g/day of CBPZ (87.5%, 14/16) than in those who were given 2g/day (57.1%, 8/14).
2) Antibacterial activity of CBPZ was evaluated in 41 isolated bacterial strains. Pathogen eradication rate by bacterial species was 75.6% (31/41). CBPZ exerted excellent antibacterial effects on Escherichia coli (100%, 8/8) and anaerobic bacteria such as Bacteroides (88.9%, 8/9). Resistant bacteria to CBPZ were Enterococcus faecalis and Pseudomonas aeruginosa.
3) No serious side effects were noted in any of the 34 patients who entered in this study. Abnormal laboratory test results were noted in 2 patients (5.9%) and they were transient elevation of transaminases and alkaline phosphatase.
From the results shown above, CBPZ appears to be a highly useful antibiotic for the treatment of surgical infection.

Corresponding author

Register with J-STAGE for free!